glasmacinal (EP395)

About EpiEndo Pharmaceuticals

EpiEndo Pharmaceuticals is developing a novel, first-in-class oral therapy for chronic obstructive pulmonary disease (COPD), a leading global cause of death. Its lead asset, glasmacinal, is a non-antibiotic macrolide (Barriolide™) that aims to reduce exacerbations by modulating the host defense response and inflammation, addressing a key limitation of chronic antibiotic use. Founded in 2016, the company is clinical-stage, backed by a strong scientific advisory board, and recently secured €9 million in convertible bond funding to advance development. EpiEndo targets a significant unmet need in a multi-billion dollar market with a potentially safer, long-term oral treatment option.

Therapeutic Areas